Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 3rd Preview)
-
Regulatory expansion for radioligand prostate cancer therapy
FDA has expanded the indication for Novartis’ radioligand therapy Pluvicto into an earlier stage of prostate cancer, approving it for PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC) in combination with an androgen receptor pathway inhibitor (ARPI). The approval is based on data from the phase 3 PSMAddition trial (NCT04720157), where the combination reduced the risk of progression or death versus ARPI plus androgen deprivation therapy (ADT) alone. In the primary analysis, PSMAddition reported a 28% reduction (HR 0.72), with an updated analysis showing a 33% reduction (HR 0.67) and a positive overall survival trend. Novartis said the expanded label nearly doubles the eligible patient population for PSMA-positive metastatic disease, reflecting broader use earlier in the treatment pathway. Clinicians will also determine eligibility using PSMA PET imaging. The expanded use widens a commercially important franchise and increases the urgency of sequencing radioligand therapy within evolving frontline prostate cancer treatment standards.
-
Leadership transition at BioNTech as it pivots further into oncology
BioNTech has named Guido Oelkers, formerly CEO of Swedish biopharma Sobi, as its next CEO, continuing the company’s shift from COVID-era mRNA manufacturing toward an oncology-focused platform. Oelkers will replace co-founder Ugur Sahin, with Oelkers scheduled to start no later than Feb. 1, 2027. In parallel, Sahin is preparing to lead a new mRNA startup, as BioNTech previously announced management changes related to the new venture. The move puts Sobi’s leadership experience into a company executing post-pandemic strategy changes, including organizational restructuring and pipeline prioritization in oncology. For investors, the appointment signals continuity in BioNTech’s international expansion plans while formalizing leadership as the company navigates its oncology transition and mRNA ecosystem split.
-
Clinical trial setbacks in cardiometabolic inflammation
Novo Nordisk’s IL-6 inhibitor ziltivekimab has failed to meet its primary cardiovascular endpoint in the phase 3 ZEUS trial, dashing expectations that lowering inflammation would translate into fewer major adverse cardiovascular events. In a late-stage study across atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation populations, ziltivekimab did not reduce the risk of cardiovascular events such as heart attack, stroke, or cardiovascular death compared with control. Novo’s shares fell nearly 9% on the news. Novo said the program’s scientific findings will inform ongoing cardiovascular research, while the asset continues to be evaluated in other studies including HERMES in heart failure and ARTEMIS in acute heart attack. The result raises pressure to show differentiating clinical benefit in a crowded cardiometabolic field while also testing the translational value of IL-6 pathway intervention for hard clinical outcomes.
-
FDA advisory committee signals pushback on Duchenne cardiomyopathy cell therapy
Capricor’s Deramiocel has been rejected again by an FDA advisory committee, with members concluding that the evidence from the HOPE-3 phase 3 trial does not provide substantial effectiveness for the therapy in Duchenne muscular dystrophy (DMD) cardiomyopathy. At the FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting, the committee voted 9–3 against approval of Deramiocel. The panel also reviewed FDA staff concerns tied to endpoints, reported hypersensitivity events, and the company’s resubmitted biologics license application materials. Deramiocel is an allogeneic cardiosphere-derived cell therapy intended to exert immunomodulatory and anti-fibrotic effects through exosome secretion. Capricor is awaiting an FDA decision under a PDUFA target date of Aug. 22. The outcome increases the likelihood that the FDA will require additional evidence or analyses before moving forward in a setting where confirmatory effectiveness remains a central regulatory gate.
-
Radiopharma dealmaking: Curium to acquire Lantheus for $8B
Curium has agreed to buy radiopharma peer Lantheus in an $8 billion deal, expanding scale in radioligand and imaging-focused oncology while reshaping the competitive landscape for radiopharmaceutical supply and commercialization. The transaction is structured at $102.5 per share for Lantheus, with the prospect of additional consideration for shareholders tied to performance targets. The announcement positions Curium to broaden its portfolio and strengthen its development and launch capabilities across nuclear medicine. In the same deal news flow, Sandoz also announced settlements related to US generic drug pricing antitrust litigation, reflecting parallel pressure on large healthcare companies across both innovation and generics portfolios. For the radiopharma market, the Lantheus acquisition would likely accelerate consolidation as companies compete to supply PSMA- and other modality-driven treatment regimens.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.